| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-11-11 | cabiralizumab (FPA008) and nivolumab | advanced solid tumors including pancreatic cancer | 1a-1b | Five Prime Therapeutics (USA - CA) BMS (USA - NY) | Cancer - Oncology |
| 2017-11-10 | avapritinib (BLU-285) | gastrointestinal stromal tumors (GIST) | 1 | Blueprint Medicines (USA - MA) | Cancer - Oncology - Rare diseases |
| 2017-11-10 | RTH258 | neovascular wet age-related macular degeneration (AMD) | 3 | Alcon (USA -TX), a Novartis subsidiary (Switzerland) | Ophtalmological diseases |
| 2017-11-09 | MVA-BN® RSV vaccine | respiratory syncytial virus infections | 2 | Bavarian Nordic (Denmark) | Infectious diseases |
| 2017-11-08 | Leukotide | acute myeloid leukemia and other hematological malignancies | preclinical | Medivir (Sweden) | Cancer - Oncology |
| 2017-11-06 | ADV7103 (tripotassium citrate monohydrate and potassium hydrogen carbonate) | distal renal tubular acidosis (dRTA) | 3 | advicenne | Rare diseases |
| 2017-11-06 | WVE-210201 | Duchenne muscular dystrophy (DMD) | 1 | Wave LIfe Sciences (USA - MA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2017-11-06 | UCART123 | acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) | 1 | Cellectis (France) | Cancer - Oncology |
| 2017-11-04 | AS902330 (sprifermin) | primary osteoarthritis of the knee | 2b | Merck KGaA (Germany) | Inflammatory diseases - Rheumatic diseases |
| 2017-11-03 | sparsentan (RE-021) | focal segmental glomerulosclerosis (FSGS) | 2 | Retrophin (USA - CA) | Rare diseases - Kidney diseases - Renal diseases |
| 2017-11-02 | Ionis-TTRRx - inotersen | TTR amyloid cardiomyopathy | 3 | GSK (UK) Ionis Pharmaceuticals (USA - CA) | Rare diseases - Genetic diseases |
| 2017-11-01 | avapritinib (BLU-285) | gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM) | preclinical | Blueprint Medicines (USA - MA) | Cancer - Oncology - Rare diseases |
| 2017-11-01 | elagolix | endometriosis | 3 | Abbvie (USA - IL) Neurocrine Biosciences (USA - CA) | Women health |
| 2017-11-01 | AVXS-101 | spinal muscular atrophy (SMA) Type 1 | 1-2 | Avexis (USA - TX), now a Novartis company (Switzerland) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2017-11-01 | SYNT001 | autoimmune diseases that are dependent upon IgG | 1a | Syntimmune (USA - MA) | Autoimmune diseases |
| 2017-11-01 | SYNT001 | Warm Autoimmune Hemolytic Anemia (WAIHA) | 1 | Syntimmune (USA - MA) | Autoimmune diseases - Rare diseases |
| 2017-11-01 | REGN2810 (cemiplimab) and INO-5401 | glioblastoma | 1b/2a | Inovio Pharmaceuticals (USA - PA) | Cancer - Oncology - Rare diseases |
| 2017-10-31 | AR101 | peanut-allergic children and adolescents 4-17 years of age | 2 | Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) | Allergic diseases |
| 2017-10-27 | EB8018 | Crohn's disease | 1 | Enterome Bioscience (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2017-10-27 | tazemetostat - EPZ-6438 (E7438) | pediatric patients with relapsed or refractory INI1-negative molecularly defined solid tumors | 1 | Epizyme (USA - MA) | Cancer - Oncology |
